Establishment of COVID-19 Convalescent Plasma Banking System in Japan - COVID-CP Banking

Tanosaki Ryuji0 个研究点目标入组 100 人开始时间: 2020年12月25日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•(1) Blood type (ABO, Rh type) and irregular antibody are negative (Keio University Hospital)
•(2) The following infectious disease screening antigen antibody test is negative or within the blood donation standard range: syphilis serological test, hepatitis B virus test (HBs antigen, HBs antibody, HBc antibody), hepatitis C virus test (HCV antibody) ), HIV test (HIV-1, 2 antibody), HTLV-1 antibody test, human parvovirus test, nucleic acid amplification test (HBV, HCV, HIV) (when antibody test of each virus becomes positive) (consigned to Nisseki And carry out)
•(3) SARS-CoV-2 neutralizing antibody titer (conducted at National Institute of Infectious Diseases Toyama Government Building) is high titer positive (1: 160 or more is a guide).
•(4) SARS-CoV-2 blood PCR (conducted at the National Institute of Infectious Diseases Murayama Government Building) is negative.

•1) A clinically meaningful irregular antibody becomes positive,
•2) The infectious disease screening is positive or out of the blood donation standard range.
•3) SARS-CoV-2 neutralizing antibody titer was judged to be low (1:80 or less is a guideline. Since the criteria are not sufficiently standardized, it will be decided in consultation with the National Institute of Infectious Diseases)
•4) SARS-CoV-2 PCR is positive
•5) The person in charge of business determines that it is inappropriate

发起方

Tanosaki Ryuji